Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vertex Gains In Vivo CRISPR Foothold With Mammoth Pact

Executive Summary

Deal Snapshot: The nearly $700m deal gives Vertex, already with a major foothold in CRISPR, access to Mammoth’s ultra-compact gene-editing technology in two diseases.

You may also be interested in...



Vertex Expands In Vivo Gene-Editing Plans With Verve Liver Disease Pact

Vertex is expanding its investments across advanced therapies again, R&D chief David Altshuler adding a second in vivo gene-editing deal to its pipeline.

Bayer Consolidates Next-Generation Gene Editing Focus With Mammoth Deal

The German major will collaborate with the US biotech to develop CRISPR gene-editing therapies, solidifying its interest in next-generation therapeutics.

Gene-Editing Companies To Watch At J.P. Morgan

Share prices for many gene-editing companies declined in 2021, but the field is burgeoning with novel approaches due to be highlighted at the J.P. Morgan meeting, and one player, Intellia, could move closer to a breakthrough in 2022.

Related Content

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel